AEE788 is a reversible inhibitor of EGFR, HER2 and VEGFR1-3 with antitumor and antiangiogenic activity. This compound has been evaluated in phase I clinical trial where inhibition of EGFR was reported.
This website requires cookies and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our Privacy Notice.
